{"id": "mf-bench-001", "category": "aimf_differential_triage", "difficulty": "medium", "question": "A 39-year-old woman with arthralgias, positive ANA (1:640 speckled), direct antiglobulin test (DAT) positivity, hemoglobin 7.6 g/dL, platelets 92 x 10^9/L, no palpable splenomegaly, and a 'dry tap' bone marrow biopsy showing WHO MF-2 reticulin fibrosis tests negative for JAK2 V617F, JAK2 exon 12, CALR exon 9, and MPL W515 mutations. Extended 54-gene myeloid NGS shows zero somatic variants (absent ASXL1, EZH2, SRSF2, U2AF1, IDH1/2, TP53) and diploid karyotype. Marrow histopathology shows non-clustered normoblastic megakaryocytes and non-paratrabecular polyclonal CD8+/CD4+ T- and CD20+ B-lymphoid aggregates without osteosclerosis. Which clinical intervention is mechanistically and empirically indicated first?", "choices": {"A": "Immunosuppressive therapy (prednisone 1 mg/kg/day taper, or rituximab / mycophenolate mofetil salvage) targeting reversible Autoimmune Myelofibrosis (AIMF), which achieves 74-80% hematologic and marrow reticulin resolution", "B": "Immediate referral for myeloablative busulfan/fludarabine allogeneic hematopoietic stem cell transplantation (allo-HSCT) for high-risk Triple-Negative Primary Myelofibrosis", "C": "Frontline ruxolitinib 20 mg BID to inhibit JAK1/JAK2 cytokine signaling and reverse clonal stromal fibrosis", "D": "Rusfertide (PTG-300) subcutaneous weekly dosing to restrict erythropoietic iron delivery and reduce marrow stress"}, "correct_choice": "A", "required_reasoning_keywords": ["Autoimmune Myelofibrosis", "non-clustered megakaryocytes", "lymphoid aggregates", "74-80%", "rituximab"], "rationale": "This presentation fulfills consensus clinicopathologic criteria for Autoimmune Myelofibrosis (AIMF; Pullarkat et al. PMID:12605397; Vergara-Lluri et al. PMID:24767860; Gangat et al. Mayo Clinic PMID:38342652): young female demographic, ANA/DAT positivity, absence of palpable splenomegaly or leukoerythroblastic teardrop poikilocytosis, non-clustered megakaryocytes without bulbous/cloud-like atypia, polyclonal lymphoid aggregates, and complete absence of JAK2/CALR/MPL or HMR myeloid driver mutations (ASXL1, SRSF2, U2AF1, EZH2). Across Mayo Clinic and French multicenter cohorts, glucocorticoids, rituximab, or MMF induce 74-80% hematologic CR and physical marrow reticulin regression within 8-16+ weeks, whereas allo-HSCT exposes a non-clonal patient to 20-35% non-relapse mortality and ruxolitinib worsens cytopenias.", "primary_citations": ["PMID:38342652", "PMID:33054116", "PMID:24767860", "PMID:12605397"]}
{"id": "mf-bench-002", "category": "aimf_differential_triage", "difficulty": "hard", "question": "A computational pathology startup is training a whole-slide image (WSI) + genomic triage model to separate true clonal Triple-Negative Primary Myelofibrosis (TN-PMF) from secondary Autoimmune Myelofibrosis (AIMF) associated with SLE, Sjogren's syndrome, Evans syndrome, or Primary Biliary Cholangitis (PBC). Which feature combination provides the highest positive predictive value for clonal TN-PMF over AIMF?", "choices": {"A": "WHO Grade MF-2 reticulin staining, polyclonal reactive lymphoid islands, polyclonal hypergammaglobulinemia, and elevated serum ferritin >1,500 ng/mL", "B": "Absence of JAK2 V617F on standard PCR alone combined with reticulin grade >=MF-2 and reticulocytopenia", "C": "Isolated normocytic anemia, non-clustered small-to-normal megakaryocytes, CD8+ T-cell predominance in interstitial aggregates, and positive anti-Ro/SSA antibodies", "D": "Tight paratrabecular and intrasinusoidal clusters (>=3-7 cells) of large hyperchromatic 'cloud-like' megakaryocytes, osteosclerosis, peripheral leukoerythroblastosis with dacryocytes, and somatic ASXL1 or SRSF2 VAF >=10%"}, "correct_choice": "D", "required_reasoning_keywords": ["megakaryocyte", "osteosclerosis", "ASXL1", "SRSF2", "TN-PMF"], "rationale": "Reticulin fibrosis grade (MF-2/MF-3) alone cannot distinguish AIMF from clonal PMF because autoimmune cytokines (TGF-beta, IFN-gamma, IL-6) stimulate dense reticulin deposition in benign stroma. As established by Vergara-Lluri et al. (PMID:24767860) and WHO/ICC myeloid criteria (ORPHA:824), clonal TN-PMF requires demonstration of megakaryocytic neoplasia (tight clustering, cloud-like/hyperchromatic nuclei, intrasinusoidal hematopoiesis, osteosclerosis) and clonal myeloid markers such as somatic ASXL1, EZH2, SRSF2, U2AF1, IDH1/2, or cytogenetic abnormalities, whereas AIMF shows unclustered megakaryocytes, lymphoid aggregates, and 0% HMR driver clonality.", "primary_citations": ["PMID:24767860", "PMID:38342652", "ORPHA:824", "GEO:GSE144568"]}
{"id": "mf-bench-003", "category": "aimf_differential_triage", "difficulty": "hard", "question": "In Mayo Clinic and French multicenter cohorts of Autoimmune Myelofibrosis (AIMF) patients who relapsed upon corticosteroid tapering or exhibited steroid-refractory lupus/Evans-associated cytopenias with MF-2/3 marrow reticulin fibrosis, what clinical outcome was observed with anti-CD20 B-cell depletion (rituximab) or mycophenolate mofetil (MMF), and why does this anchor 'Nature's Positive Control' for antifibrotic drug discovery?", "choices": {"A": "0% marrow reticulin change despite transient hemoglobin stabilization, proving adult human bone marrow reticulin cannot be enzymatically degraded once cross-linked", "B": "Rapid transformation to TP53-mutant acute myeloid leukemia within 6 months due to immunosuppressive loss of T-cell tumor surveillance", "C": "~80% complete hematologic response on rituximab salvage accompanied by histological resolution or >=1-2 grade regression of bone marrow reticulin fibrosis within months, proving human marrow stromal myofibroblasts revert when the upstream immune/cytokine driver is extinguished", "D": "Selective clearance of CALR exon 9 frameshift stem cells via antibody-dependent cellular cytotoxicity"}, "correct_choice": "C", "required_reasoning_keywords": ["rituximab", "80%", "reticulin", "stromal", "reversible"], "rationale": "Gangat et al. (Mayo Clinic, PMID:38342652) and Mertz et al. (French cohort, PMID:33054116) documented 74% overall CR to frontline steroids and 80% CR on rituximab salvage, with repeat trephine biopsies showing objective regression/complete resolution of marrow reticulin fibrosis. Translationally, AIMF proves that adult human LepR+/GLI1+ marrow stromal cells possess endogenous matrix metalloproteinase (MMP) remodeling capacity once pathogenic paracrine signaling ceases—contrasting with clonal JAK2 V617F+ PMF where persistent megakaryocytic S100A8/A9 and TGFB1 lock myofibroblasts in an active state (GEO:GSE156644).", "primary_citations": ["PMID:38342652", "PMID:33054116", "GEO:GSE156644"]}
{"id": "mf-bench-004", "category": "aimf_differential_triage", "difficulty": "medium", "question": "Why does empiric initiation of a Type I JAK1/JAK2 inhibitor (such as ruxolitinib 15-20 mg BID) prior to completing autoimmune serology and extended myeloid NGS create a dual clinical and diagnostic hazard in a transfusion-dependent patient with suspected Triple-Negative Myelofibrosis who actually has Primary AIMF?", "choices": {"A": "Ruxolitinib irreversibly cross-links marrow collagen I/III via lysyl oxidase activation within 14 days", "B": "Pan-JH1 wild-type JAK2 inhibition suppresses EPOR and MPL signaling—exacerbating severe anemia and thrombocytopenia—while partial JAK1 cytokine dampening transiently masks autoimmune fever/CRP without reliably clearing B-cell autoantibodies, delaying curative steroid/rituximab therapy at ~$18,000-$20,000/month cost", "C": "Ruxolitinib induces somatic JAK2 V617F point mutations de novo in polyclonal CD8+ T lymphocytes", "D": "Type I JAK inhibitors selectively upregulate hepatic ferroportin and trigger acute fatal hemochromatosis within 72 hours"}, "correct_choice": "B", "required_reasoning_keywords": ["EPOR", "MPL", "wild-type JAK2", "cytopenia", "autoantibodies"], "rationale": "In AIMF, hematopoiesis relies entirely on normal wild-type JAK2 downstream of erythropoietin (EPOR) and thrombopoietin (MPL) receptors. Inhibiting wild-type JH1 with ruxolitinib aggravates transfusion-dependent anemia and thrombocytopenia without eliminating autoreactive CD20+ B-cell clones, while partial anti-JAK1 anti-inflammatory effects can obscure rheumatologic workup and waste >$200K/yr compared with inexpensive, disease-resolving prednisone, MMF, or rituximab (PMID:38342652, PMID:33054116).", "primary_citations": ["PMID:38342652", "PMID:33054116", "NCT00952289"]}
{"id": "mf-bench-005", "category": "aimf_differential_triage", "difficulty": "hard", "question": "A 66-year-old man presents with transfusion-dependent macrocytic anemia (MCV 108 fL), relapsing auricular chondritis, neutrophilic dermatosis, CRP 115 mg/L, Grade MF-1/2 marrow reticulin, cytoplasmic vacuoles in erythroid and myeloid precursors, negative JAK2/CALR/MPL, and negative ANA/dsDNA. Before labeling this case 'idiopathic seronegative AIMF' or 'TN-PMF', which specific somatic gene locus must be sequenced and why?", "choices": {"A": "X-linked UBA1 (particularly codon p.Met41Thr/Val/Leu and splice sites), because VEXAS syndrome mimics refractory autoimmune/myelofibrotic marrow failure in men >50 yet arises from a somatic myeloid E1 ubiquitin-activating enzyme clone that relapses severely upon steroid taper", "B": "Germline HFE p.Cys282Tyr homozygosity, which accounts for >90% of vacuolated myeloid precursors and auricular chondritis", "C": "TPSAB1 alpha-tryptase copy-number triplication, the causal driver of macrocytic vacuolated chondritis", "D": "BCR::ABL1 p190 transcript only, since X-linked myeloid genes are universally included on legacy 20-gene MPN panels"}, "correct_choice": "A", "required_reasoning_keywords": ["UBA1", "Met41", "VEXAS", "vacuoles", "macrocytic"], "rationale": "Somatic X-linked UBA1 p.Met41 mutations cause VEXAS syndrome (Beck et al., NEJM 2020 PMID:33113032; ORPHA:597743), affecting ~1 in 4,269 men over age 50. VEXAS frequently presents with rheumatologic syndromes, macrocytic anemia (MCV >100 fL), cytoplasmic vacuoles in marrow precursors, and mild-to-moderate reticulin fibrosis while testing negative for JAK2/CALR/MPL and routine autoantibodies. Unlike polyclonal AIMF—which achieves durable off-steroid remission after short-course steroids/rituximab—VEXAS is driven by a clonal UBA1c-expressing HSPC population requiring UBA1-informed trials (PAXIS pacritinib NCT06538181 or reduced-intensity allo-HSCT NCT05027945).", "primary_citations": ["PMID:33113032", "ORPHA:597743", "NCT05027945", "NCT06538181", "GEO:GSE163683"]}
{"id": "mf-bench-006", "category": "aimf_differential_triage", "difficulty": "hard", "question": "A 44-year-old patient in ICU crisis exhibits severe thrombocytopenia (18 x 10^9/L), generalized anasarca, fever, renal dysfunction, hepatosplenomegaly, MF-2 bone marrow reticulin fibrosis with megakaryocytic hyperplasia, negative JAK2/CALR/MPL, negative HHV-8, negative ANA/anti-dsDNA, and an excisional lymph node biopsy showing atrophic germinal centers, 'lollipop' penetrating hyalinized vessels, and interfollicular vascular/plasmacytic proliferation. How should an AI diagnostic triage system classify and route this case?", "choices": {"A": "Clonal JAK2-unmutated Essential Thrombocythemia; route to hydroxyurea cytoreduction", "B": "Indolent Systemic Mastocytosis; order avapritinib 25 mg QD", "C": "Classic Pediatric Dyskeratosis Congenita; initiate high-dose danazol monotherapy", "D": "Idiopathic Multicentric Castleman Disease - TAFRO subtype (iMCD-TAFRO, ORPHA:93685), a cytokine-driven secondary myelofibrosis mimic requiring urgent anti-IL-6 (siltuximab) +/- corticosteroids, with calcineurin/sirolimus (mTOR, NCT03933904) or JAK1/2 salvage if siltuximab-refractory"}, "correct_choice": "D", "required_reasoning_keywords": ["iMCD-TAFRO", "ORPHA:93685", "siltuximab", "IL-6", "sirolimus"], "rationale": "iMCD-TAFRO (Thrombocytopenia, Anasarca, Fever, Reticulin myelofibrosis, Organomegaly; ORPHA:93685) produces prominent non-clonal bone marrow reticulin fibrosis driven by systemic IL-6, VEGF, and mTOR/JAK-STAT hyperactivation and is frequently misdiagnosed as SLE-AIMF, TTP, or TN-PMF in the ICU. Consensus CDCN lymph-node histopathology (regressed germinal centers + hypervascularity) separates iMCD-TAFRO from AIMF and directs immediate anti-IL-6 therapy (siltuximab) or mTOR inhibition (sirolimus, NCT03933904) for the 60-66% siltuximab-refractory fraction.", "primary_citations": ["ORPHA:93685", "NCT03933904", "PMID:28100462"]}
{"id": "mf-bench-007", "category": "iron_hepcidin_axis", "difficulty": "medium", "question": "An untransfused patient with newly diagnosed SLE-associated Autoimmune Myelofibrosis (or hyperinflammatory PMF) presents with hemoglobin 8.1 g/dL, serum ferritin 1,450 ng/mL, serum iron 24 mcg/dL (low), total iron-binding capacity (TIBC) 175 mcg/dL (low), transferrin saturation (TSAT) 14%, and 3+ reticuloendothelial macrophage hemosiderin on marrow Prussian blue stain with absent ring sideroblasts. What molecular pathway explains this iron paradox?", "choices": {"A": "Direct proteolytic cleavage of transferrin by mutant CALR in peripheral plasma", "B": "Complete bi-allelic deletion of HAMP suppresses hepcidin to zero, causing uncontrolled duodenal iron hyperabsorption and TSAT >90%", "C": "Somatic SF3B1 K700E mutation traps iron exclusively inside erythroblast mitochondria while depleting macrophage ferritin", "D": "Elevated IL-6 and BMP6/ACVR1 signaling activate hepatic JAK/STAT3 and SMAD1/5/8 transcription of HAMP (hepcidin), inducing internalization and lysosomal degradation of SLC40A1 (ferroportin) on marrow macrophages and enterocytes—trapping iron intracellularly while starving erythroid precursors"}, "correct_choice": "D", "required_reasoning_keywords": ["IL-6", "STAT3", "HAMP", "SLC40A1", "ferroportin"], "rationale": "Both hyperinflammatory PMF and AIMF exhibit classic high-hepcidin functional iron restriction: systemic IL-6 (via JAK1/2-STAT3) and hepatic BMP6/ACVR1 (ALK2-SMAD1/5/8) drive excess HAMP (hepcidin) secretion. Hepcidin binds and triggers ubiquitination/degradation of the sole cellular iron exporter SLC40A1 (ferroportin), sequestering recycled senescent-RBC iron inside marrow macrophages (high serum ferritin, 3+ macrophage Prussian blue staining) while lowering circulating serum iron, TIBC, and TSAT (<20%), causing iron-restricted erythropoiesis (PMID:36720133, PMID:38342652).", "primary_citations": ["PMID:36720133", "PMID:38342652", "NCT04173494"]}
{"id": "mf-bench-008", "category": "iron_hepcidin_axis", "difficulty": "hard", "question": "Contrast Patient 1 (untransfused inflammatory MF: ferritin 1,100 ng/mL, low TIBC, TSAT 13%, high hepcidin) with Patient 2 (heavily transfused MF/AIMF after 28 units PRBCs: ferritin 3,400 ng/mL, TSAT 88%, elevated non-transferrin-bound iron [NTBI] and labile plasma iron [LPI], hepatic R2* MRI iron 14 mg/g dry weight). Which therapeutic pairing is mechanistically sound?", "choices": {"A": "Administer intravenous high-molecular-weight iron dextran to Patient 2 and deferasirox iron chelation to Patient 1", "B": "Administer the hepcidin mimetic rusfertide (PTG-300) to both patients to normalize ferritin", "C": "Address Patient 1's functional iron block by suppressing the ACVR1/ALK2 or IL-6 -> HAMP hepcidin axis (e.g., momelotinib in clonal MF or anti-inflammatory/immunosuppressive therapy in AIMF), whereas Patient 2 has true parenchymal transfusional hemosiderosis with toxic NTBI/LPI requiring iron chelation (e.g., deferasirox) alongside erythropoietic recovery", "D": "Perform therapeutic phlebotomy of 500 mL whole blood weekly in Patient 2 despite hemoglobin 7.2 g/dL"}, "correct_choice": "C", "required_reasoning_keywords": ["ACVR1", "momelotinib", "NTBI", "LPI", "deferasirox"], "rationale": "Patient 1 does not have total-body parenchymal iron excess; iron is compartmentalized in macrophages due to elevated hepcidin (TSAT 13%), so iron chelation worsens erythropoietic iron starvation whereas ACVR1/ALK2 inhibition (momelotinib, MOMENTUM NCT04173494) or IL-6/autoimmune suppression lowers hepcidin and restores ferroportin export. Conversely, each PRBC unit adds ~200-250 mg of non-excretable iron; after 28 units (~6-7 g iron), Patient 2 saturates transferrin (TSAT >80%), generating redox-active NTBI/LPI that damages hepatocytes, cardiomyocytes, and marrow stroma—requiring oral iron chelation (deferasirox) because severe anemia precludes phlebotomy.", "primary_citations": ["NCT04173494", "PMID:36720133", "PMID:38342652"]}
{"id": "mf-bench-009", "category": "iron_hepcidin_axis", "difficulty": "medium", "question": "Rusfertide (PTG-300) is a subcutaneous peptidic hepcidin mimetic evaluated in Phase 3 Polycythemia Vera (VERIFY, NCT05210790) to eliminate therapeutic phlebotomies. Why is rusfertide strictly contraindicated as an anemia therapy in transfusion-dependent Primary Myelofibrosis or Autoimmune Myelofibrosis?", "choices": {"A": "Rusfertide is a direct JH2 V617F agonist that accelerates megakaryocytic proliferation", "B": "As a synthetic hepcidin mimetic, rusfertide degrades ferroportin (SLC40A1) to intentionally restrict iron availability to erythroid progenitors—beneficial for curbing autonomous RBC overproduction in JAK2+ Polycythemia Vera, but directly worsening iron-restricted anemia in MF and AIMF where hepcidin is already pathologically elevated", "C": "Rusfertide chelates mitochondrial copper and induces Wernicke encephalopathy", "D": "Rusfertide selectively depletes CD20+ B lymphocytes and causes hypogammaglobulinemia"}, "correct_choice": "B", "required_reasoning_keywords": ["rusfertide", "hepcidin mimetic", "SLC40A1", "Polycythemia Vera", "iron-restricted"], "rationale": "Polycythemia Vera (PV) and anemic Myelofibrosis sit at opposite poles of the hepcidin-ferroportin axis. PV patients have suppressed hepcidin and hyperactive erythropoiesis, so a hepcidin mimetic (rusfertide, NCT05210790) degrades SLC40A1 to induce therapeutic iron restriction and control hematocrit <45%. In anemic MF or AIMF, endogenous hepcidin is already dangerously high due to IL-6 and BMP6/ACVR1 signaling; adding a hepcidin mimetic further locks iron in macrophages and deepens transfusion dependence, whereas MF requires hepcidin *suppression* (e.g., ACVR1 inhibition via momelotinib NCT04173494 or pacritinib NCT02055781).", "primary_citations": ["NCT05210790", "NCT04173494", "NCT02055781", "PMID:36720133"]}
{"id": "mf-bench-010", "category": "iron_hepcidin_axis", "difficulty": "hard", "question": "In Phase 3 MOMENTUM (NCT04173494) and SIMPLIFY-1 (NCT01969838), momelotinib achieved substantially higher transfusion-independence rates than ruxolitinib or danazol despite inhibiting JH1 wild-type JAK2. Which off-JAK kinase target of momelotinib mediates this erythropoietic rescue, and does pacritinib share activity on this target?", "choices": {"A": "ACVR1 (ALK2) Type I bone morphogenetic protein (BMP) receptor kinase inhibition, which attenuates hepatic BMP6 -> SMAD1/5/8 -> HAMP transcription to lower circulating hepcidin and restore SLC40A1 iron mobilization; pacritinib also potently inhibits ACVR1 alongside IRAK1", "B": "FLT3 kinase inhibition; shared exclusively with fedratinib", "C": "XPO1 nuclear export inhibition; shared exclusively with selinexor", "D": "Direct allosteric activation of erythropoietin receptor (EPOR) transmembrane dimers"}, "correct_choice": "A", "required_reasoning_keywords": ["ACVR1", "ALK2", "SMAD", "HAMP", "pacritinib"], "rationale": "Momelotinib inhibits JAK1, JAK2, and ACVR1 (ALK2; IC50 ~8 nM). Blocking hepatic ACVR1 suppresses BMP6-driven SMAD1/5/8 phosphorylation at the HAMP promoter, acutely lowering serum hepcidin, restoring ferroportin (SLC40A1) export of macrophage iron, raising serum iron/hemoglobin, and driving transfusion independence (Verstovsek et al., Lancet 2023 PMID:36720133; NCT04173494). Biochemical and clinical profiling later demonstrated that pacritinib (PERSIST-2, NCT02055781) also potently inhibits ACVR1 (and IRAK1) while sparing JAK1, whereas ruxolitinib and fedratinib lack ACVR1 inhibition.", "primary_citations": ["NCT04173494", "NCT01969838", "NCT02055781", "PMID:36720133"]}
{"id": "mf-bench-011", "category": "iron_hepcidin_axis", "difficulty": "hard", "question": "How does unchelated transfusional iron overload (TSAT >75%, elevated labile plasma iron [LPI]) directly interact with the bone marrow mesenchymal stromal microenvironment (GEO:GSE156644) to accelerate both hematopoietic failure and fibrotic remodeling in chronic MF and AIMF?", "choices": {"A": "NTBI cannot enter the bone marrow cavity due to a blood-marrow tight-junction barrier impermeable to divalent cations", "B": "LPI selectively binds and degrades COL1A1 and COL3A1 fibrils, causing spontaneous resolution of marrow fibrosis", "C": "Excess free iron directly inhibits lysyl oxidase-like 2 (LOXL2) and prevents megakaryocyte polyploidization", "D": "LPI enters marrow HSPCs and LepR+/GLI1+ mesenchymal stromal cells via non-transferrin transporters, catalyzing Fenton-reaction reactive oxygen species (ROS) and lipid peroxidation that overwhelm GPX4 defense—inducing erythroid/HSPC ferroptosis while activating redox-sensitive NF-kB, NLRP3, S100A8/A9, and TGFB1 profibrotic transcription"}, "correct_choice": "D", "required_reasoning_keywords": ["LPI", "ROS", "GPX4", "ferroptosis", "TGFB1"], "rationale": "Once transferrin saturation exceeds ~70-75%, redox-active LPI bypasses transferrin receptor regulation to accumulate in erythroid progenitors and marrow mesenchymal stromal cells. Fenton-generated hydroxyl radicals drive polyunsaturated phospholipid peroxidation; when glutathione peroxidase 4 (GPX4) capacity is exceeded, normal HSPCs undergo ferroptosis (deepening cytopenias), while sublethal stromal ROS activates TGF-beta1, S100A8/S100A9 alarmins, and myofibroblast collagen deposition—explaining why iron chelation (deferasirox) can produce hematologic improvement in heavily transfused MF/MDS patients (GEO:GSE156644, PMID:33301706).", "primary_citations": ["GEO:GSE156644", "PMID:33301706", "PMID:38342652"]}
{"id": "mf-bench-012", "category": "iron_hepcidin_axis", "difficulty": "hard", "question": "In Mayo Clinic's Autoimmune Myelofibrosis cohort (Gangat et al., PMID:38342652), ~59% of patients required red blood cell transfusions prior to accurate AIMF diagnosis, frequently exhibiting concurrent SLE nephritis or autoimmune hemolytic anemia (AIHA) and ferritin >2,000 ng/mL. What serial biomarker trajectory confirms that a dual-pathology patient has transitioned from mixed inflammatory + transfusional iron overload to pure residual parenchymal hemosiderosis after rituximab/steroid remission?", "choices": {"A": "Emergence of a somatic JAK2 exon 12 mutation with serum ferritin <15 ng/mL", "B": "Rising CRP >100 mg/L, falling TSAT <10%, and rising platelet count >1,000 x 10^9/L", "C": "Normalization of CRP/ESR and recovery of transfusion-independent hemoglobin >11 g/dL (indicating resolution of IL-6 -> HAMP macrophage trapping), paired with persistently elevated TSAT (>50-60%), ferritin >1,000 ng/mL, and elevated hepatic MRI R2* iron concentration", "D": "Persistent DAT+ reticulocytopenia with undetectable serum iron and TIBC >450 mcg/dL"}, "correct_choice": "C", "required_reasoning_keywords": ["CRP", "TSAT", "ferritin", "MRI", "hemosiderosis"], "rationale": "During active untreated AIMF, hyperferritinemia is a composite of IL-6/hepcidin-mediated macrophage trapping AND exogenous PRBC iron loading (200-250 mg Fe/unit). Once immunosuppression (steroids/rituximab) extinguishes autoimmune inflammation, CRP and hepcidin normalize, SLC40A1 is restored, and hemoglobin recovers without transfusions. If ferritin (>1,000 ng/mL), TSAT (>50%), and liver MRI R2* remain elevated after CRP normalizes, the remaining burden reflects true non-excreted transfusional parenchymal iron eligible for targeted chelation or cautious post-remission phlebotomy once Hb is safely normalized (PMID:38342652).", "primary_citations": ["PMID:38342652", "PMID:33054116"]}
{"id": "mf-bench-013", "category": "jak2_jh2_structural_selectivity", "difficulty": "medium", "question": "Crystallographic comparison of wild-type human JAK2 JH2 pseudokinase domain (PDB:4FVP) against the somatic JAK2 V617F mutant JH2 domain (PDB:4FVQ, PDB:4FVR) revealed the atomic mechanism by which p.Val617Phe relieves JH2-mediated autoinhibition of the JH1 catalytic kinase domain. Which structural rearrangement directly stabilizes the constitutive active conformation?", "choices": {"A": "Val617Phe mutates the catalytic Asp-Phe-Gly (DFG) motif inside the JH1 kinase domain, covalently trapping Mg-ATP", "B": "Val617Phe deletes the FERM domain, preventing JAK2 from binding cytoplasmic box1/box2 motifs of EPOR and MPL", "C": "Substitution of Val617 in the JH2 beta4-beta5 loop with bulky aromatic Phe617 creates face-to-edge pi-pi aromatic stacking with JH2 alphaC-helix residue Phe595 (and SH2-JH2 linker Phe537), rigidifying and lengthening the JH2 alphaC helix to disrupt inhibitory JH2-JH1 contacts and promote cytokine-independent trans-phosphorylation", "D": "Val617Phe introduces a disulfide bond between two extracellular MPL cytokine-binding domains"}, "correct_choice": "C", "required_reasoning_keywords": ["JH2", "F595", "F537", "alphaC", "PDB:4FVQ"], "rationale": "Bandaranayake et al. (Nat Struct Mol Biol 2012, PMID:22820988; PDB:4FVP vs PDB:4FVQ/4FVR) demonstrated that replacing aliphatic Val617 in JH2 with Phe617 nucleates an intramolecular aromatic pi-stacking triad with Phe595 on the JH2 alphaC helix and Phe537 in the SH2-JH2 linker. Mutating Phe595 to non-aromatic residues abolishes V617F constitutive activation while preserving wild-type cytokine-inducible signaling—defining the exact allosteric triad exploited by mutant-selective JH2 drug discovery.", "primary_citations": ["PDB:4FVP", "PDB:4FVQ", "PDB:4FVR", "PMID:22820988"]}
{"id": "mf-bench-014", "category": "jak2_jh2_structural_selectivity", "difficulty": "medium", "question": "Why do all four currently FDA-approved Myelofibrosis JAK inhibitors (ruxolitinib, fedratinib, pacritinib, momelotinib) fail to achieve wild-type vs JAK2 V617F clonal selectivity and consequently face a dose-limiting myelosuppression ceiling?", "choices": {"A": "They bind irreversibly to Cys480 in the JAK2 SH2 domain, which is absent in hematopoietic stem cells", "B": "They are Type I ATP-competitive binders targeting the JH1 catalytic kinase hinge (Glu930/Leu932), whose active-site sequence and geometry are 100% identical between wild-type JAK2 and JAK2 V617F—blocking obligatory wild-type JAK2 signaling downstream of EPOR (erythropoiesis) and MPL/TPOR (thrombopoiesis)", "C": "They selectively degrade mutant CALR while upregulating wild-type JAK2 transcription 10-fold", "D": "They cannot cross the plasma membrane of CD34+ hematopoietic stem and progenitor cells"}, "correct_choice": "B", "required_reasoning_keywords": ["JH1", "Type I", "wild-type JAK2", "EPOR", "MPL"], "rationale": "Because Val617Phe resides in the regulatory JH2 pseudokinase domain while ruxolitinib (PDB:3KRR), fedratinib, pacritinib, and momelotinib bind the conserved JH1 catalytic ATP-binding pocket (hinge residues Glu930/Leu932) in the active DFG-in state, these agents inhibit wild-type JAK2 equipotently with JAK2 V617F. Since normal red cell and platelet production depend strictly on wild-type JAK2 homodimers coupled to EPOR and MPL, exposures sufficient to eradicate mutant HSC clones cause intolerable Grade 3/4 anemia and thrombocytopenia.", "primary_citations": ["PDB:3KRR", "PDB:4FVR", "NCT00952289", "NCT06313593"]}
{"id": "mf-bench-015", "category": "jak2_jh2_structural_selectivity", "difficulty": "hard", "question": "Chronic exposure of JAK2 V617F+ MPN cells to Type I JH1 inhibitors (such as ruxolitinib) induces adaptive 'Type I JAK2 inhibitor persistence' without acquiring secondary JH1 gatekeeper mutations, followed by severe cytokine rebound upon abrupt drug withdrawal. How does Type II DFG-out JAK2 inhibition (e.g., CHZ868 preclinical proof-of-concept; clinical entrant AJ1-11095, NCT06343805) overcome this persistence state?", "choices": {"A": "Type I inhibitors lock JH1 in an active DFG-in conformation that shields activation-loop Tyr1007/Tyr1008 from phosphatases, causing accumulation of hyperphosphorylated JAK2 that heterodimerizes with JAK1 and TYK2 to reactivate STAT3/5; Type II inhibitors bind the inactive DFG-out pocket, preventing activation-loop phosphorylation, collapsing heterodimer trans-activation, and depleting mutant VAF", "B": "Type II inhibitors covalently alkylate STAT5 SH2 domains without interacting with JAK2", "C": "Type I persistence is caused by MDR1 P-glycoprotein drug efflux, which AJ1-11095 bypasses via intrathecal administration", "D": "Type II inhibitors selectively agonize IL-6 receptors to exhaust mutant stem cells"}, "correct_choice": "A", "required_reasoning_keywords": ["Y1007/Y1008", "heterodimer", "JAK1", "DFG-out", "AJ1-11095"], "rationale": "Koppikar et al. (Nature 2012, PMID:22897849) showed that Type I ATP-competitive binding stabilizes JAK2 in an active DFG-in state with paradoxical hyperphosphorylation of activation-loop Y1007/Y1008, enabling heterodimerization and trans-activation by JAK1 and TYK2 (and explosive signaling upon washout). Meyer et al. (Cancer Cell 2015, PMID:26175413; PDB:5UT1) proved that Type II inhibitors stabilize the inactive DFG-out conformation (Asp994-Phe995-Gly996 flipped), abolishing Y1007/Y1008 hyperphosphorylation, reversing persistence, and reducing mutant allele burden—the clinical thesis behind AJ1-11095 (NCT06343805).", "primary_citations": ["PMID:22897849", "PMID:26175413", "PDB:5UT1", "NCT06343805"]}
{"id": "mf-bench-016", "category": "jak2_jh2_structural_selectivity", "difficulty": "hard", "question": "Compare the subcellular localization and modality tractability of the two major MPN drivers: somatic CALR exon 9 (+1 bp frameshift, e.g., Type 1 52-bp del / Type 2 5-bp ins) versus somatic JAK2 V617F. Why can INCA033989 (NCT06034002) target mutant CALR as a naked/engineered monoclonal antibody, whereas selective targeting of JAK2 V617F (e.g., INCB160058, NCT06313593, or JH2 PROTACs) requires cell-permeable small molecules?", "choices": {"A": "Wild-type and mutant JAK2 are secreted soluble plasma cytokines, whereas mutant CALR is restricted to the inner mitochondrial matrix", "B": "INCA033989 crosses the plasma membrane via transferrin transcytosis to bind cytoplasmic STAT5", "C": "JAK2 V617F lacks any crystal structures, preventing antibody humanization", "D": "CALR frameshift mutations abolish the ER-retention KDEL motif and generate a novel positively charged C-terminal peptide that complexes with N-glycosylated MPL and traffics to the external plasma membrane surface (accessible to mAb INCA033989), whereas JAK2 V617F is strictly intracellular on cytosolic receptor tails—requiring cell-permeable JH2 allosteric inhibitors or CRBN/VHL degraders"}, "correct_choice": "D", "required_reasoning_keywords": ["KDEL", "cell surface", "MPL", "INCA033989", "INCB160058"], "rationale": "All pathogenic CALR exon 9 indels shift into the same +1 reading frame, replacing the acidic C-terminus and ER-retaining KDEL sequence with a shared basic neo-C-terminus. Mutant CALR oligomers bind immature N-glycans on MPL in the ER/Golgi and escort constitutively active CALRmut-MPL complexes to the extracellular cell surface of HSPCs and megakaryocytes, making them directly druggable by surface mAbs/bispecifics (INCA033989, NCT06034002). By contrast, JAK2 V617F resides entirely in the cytoplasm bound to box1/box2 receptor tails, necessitating oral cell-permeable JH2 ligands (INCB160058, NCT06313593) or intracellular PROTAC degraders.", "primary_citations": ["NCT06034002", "NCT06313593", "PDB:4FVR", "PDB:7F7W"]}
{"id": "mf-bench-017", "category": "jak2_jh2_structural_selectivity", "difficulty": "hard", "question": "When designing a mutant-selective JAK2 V617F heterobifunctional PROTAC degrader anchored in the JH2 pseudokinase ATP-like pocket (PDB:4FVR, PDB:6VNE, PDB:8BAK, PDB:8EX2) rather than a reversible stoichiometric JH2 inhibitor, what biophysical and pharmacological advantage can a catalytic degrader achieve?", "choices": {"A": "Degrading JAK2 V617F permanently edits genomic DNA in exon 14 back to wild-type guanine", "B": "PROTACs have molecular weights <180 Da that guarantee 100% blood-brain barrier penetration into CNS microglia", "C": "A JH2-anchored PROTAC can leverage moderate binary binding selectivity amplified by cooperative ternary-complex formation (alpha > 1) with CRBN or VHL to ubiquitylate and eliminate the entire JAK2 V617F protein scaffold—preventing both JH1 catalytic leakage and JAK1/TYK2 heterodimer scaffolding at sub-stoichiometric doses while sparing wild-type JAK2", "D": "JH2 PROTACs require covalent binding to the JH1 Leu932 hinge to recruit the 26S proteasome"}, "correct_choice": "C", "required_reasoning_keywords": ["PROTAC", "ternary", "CRBN", "scaffolding", "PDB:8BAK"], "rationale": "Because the JH2 nucleotide pocket shares partial homology with JH1 and wild-type JH2, purely occupancy-driven JH2 inhibitors require continuous high target engagement to suppress allosteric transmission to JH1. A solvent-exposed exit vector from the V617F-remodeled JH2 pocket (PDB:8BAK, PDB:8EX2, PDB:6VNE) recruiting CRBN or VHL can exploit differential lysine presentation and positive ternary cooperativity to catalytically destroy mutant JAK2 V617F protein—eliminating non-catalytic scaffolding and heterodimer persistence while leaving wild-type JAK2 homodimers intact.", "primary_citations": ["PDB:4FVR", "PDB:6VNE", "PDB:8BAK", "PDB:8EX2"]}
{"id": "mf-bench-018", "category": "jak2_jh2_structural_selectivity", "difficulty": "hard", "question": "Across the Rare Disease Venture Atlas's comparative myeloid kinase/enzyme cohort, how does the structural selectivity challenge of JAK2 V617F JH2 in Myelofibrosis compare with KIT D816V in Systemic Mastocytosis (ORPHA:2467; PDB:4U0I vs PDB:1T46)?", "choices": {"A": "Both mutations are loss-of-function deletions in extracellular immunoglobulin domains treated with enzyme replacement therapy", "B": "JAK2 V617F is an allosteric pseudokinase (JH2) mutation requiring JH2-over-JH1 and V617F-over-WT selectivity to prevent peripheral cytopenias, whereas KIT D816V is a catalytic activation-loop mutation locking JH1 in an active Type I state (rendering Type II imatinib inactive) where next-gen clinical optimization (bezuclastinib NCT05186753, elenestinib NCT04910685) must pair WT-KIT/PDGFRA selectivity with strict blood-brain barrier efflux (Kp,uu < 0.02) to avoid avapritinib-like CNS toxicity", "C": "KIT D816V is sensitive to low-dose Type II imatinib (IC50 0.1 nM), whereas JAK2 V617F requires CNS-penetrant brain exposure", "D": "Neither target has high-resolution human PDB crystal structures available for structure-based design"}, "correct_choice": "B", "required_reasoning_keywords": ["KIT D816V", "activation-loop", "PDB:4U0I", "Kp,uu", "NCT05186753"], "rationale": "Comparing the two somatic myeloid drivers highlights orthogonal medicinal chemistry constraints: JAK2 V617F sits outside the catalytic domain in JH2 (PDB:4FVQ/4FVR), so avoiding anemia/thrombocytopenia requires sparing WT JAK2 JH1/JH2. Conversely, KIT D816V sits directly in the catalytic activation loop (PDB:4U0I vs autoinhibited PDB:1T46), conferring steric/conformational resistance to Type II imatinib; first-gen Type I D816V inhibitor avapritinib (NCT03731260) crossed the BBB causing cognitive/intracranial-bleed liabilities, making peripheral restriction (P-gp efflux, Kp,uu < 0.02) + PDGFRA sparing the core optimization wedge in SUMMIT (NCT05186753) and HARBOR (NCT04910685).", "primary_citations": ["PDB:4U0I", "PDB:1T46", "ORPHA:2467", "NCT05186753", "NCT04910685"]}
{"id": "mf-bench-019", "category": "clinical_trial_forensics", "difficulty": "medium", "question": "In Phase 3 frontline Myelofibrosis combination trials MANIFEST-2 (pelabresib + ruxolitinib, NCT04603495) and TRANSFORM-1 (navitoclax + ruxolitinib, NCT04472598), both experimental arms roughly doubled Week-24 Spleen Volume Reduction >=35% (SVR35 >63% vs ~31-35% on ruxolitinib + placebo), yet both missed statistical significance on the dual/key secondary Total Symptom Score >=50% reduction (TSS50) endpoint. What primary methodological and clinical factor drove this SVR35/TSS50 dissociation?", "choices": {"A": "Ruxolitinib + placebo achieved 0% TSS50 in both studies due to complete receptor desensitization", "B": "Ruxolitinib monotherapy already saturates acute JAK1-mediated inflammatory cytokine symptom relief (~45-55% TSS50 ceiling), while dichotomous TSS50 diary scoring suffers from baseline lower-symptom dilution and overlapping drug-induced fatigue/GI/cytopenia adverse events—obscuring biologic marrow reticulin, hemoglobin, and VAF signals when disease modification is judged solely at Week 24 by TSS50", "C": "MRI/CT spleen volumetry has >90% measurement error compared with manual abdominal palpation", "D": "Pelabresib and navitoclax both block ruxolitinib intestinal absorption by >85%"}, "correct_choice": "B", "required_reasoning_keywords": ["SVR35", "TSS50", "MANIFEST-2", "NCT04603495", "cytokine"], "rationale": "Symptom improvement on MF-SAF v4.0 (night sweats, fever, pruritus, cachexia) is heavily driven by JAK1/STAT3 cytokine suppression, which active-control ruxolitinib already achieves robustly (~45-53% TSS50). Adding an epigenetic BET inhibitor (pelabresib, NCT04603495) or BCL-XL inhibitor (navitoclax, NCT04472598) deepens splenic and marrow clone/megakaryocyte reductions (doubling SVR35 and improving marrow reticulin grade in MANIFEST-2), but binary 50% symptom cutoffs at Week 24 penalize mild GI/thrombocytopenic fatigue and fail to capture long-term clonal or antifibrotic disease modification.", "primary_citations": ["NCT04603495", "NCT04472598", "NCT00952289"]}
{"id": "mf-bench-020", "category": "clinical_trial_forensics", "difficulty": "hard", "question": "What landmark regulatory precedent did the Phase 3 IMpactMF trial of imetelstat (NCT04576156) establish in JAK-inhibitor-relapsed/refractory Myelofibrosis, and what strategic lesson does its trial architecture impart for post-ruxolitinib drug development?", "choices": {"A": "IMpactMF was the first Phase 3 Myelofibrosis trial built around Overall Survival (OS) rather than Week-24 SVR35 as its primary registrational endpoint against Best Available Therapy (excluding JAKi); while elevating OS as the gold-standard disease-modification benchmark, relying on unstratified late-salvage OS without a validated early clonal/fibrosis surrogate carries multi-year readout latency, crossover confounding, and high Phase 3 interim futility risk", "B": "IMpactMF used 14-day serum tryptase normalization as its sole accelerated-approval endpoint in frontline ET", "C": "IMpactMF proved that oral telomerase activators cure 95% of JAK2 V617F+ patients within 8 weeks", "D": "IMpactMF enrolled exclusively pediatric Dyskeratosis Congenita patients to claim a Rare Pediatric PRV"}, "correct_choice": "A", "required_reasoning_keywords": ["IMpactMF", "imetelstat", "NCT04576156", "Overall Survival", "surrogate"], "rationale": "Because median survival after ruxolitinib discontinuation is only 11-23 months and imetelstat (hTERT telomerase inhibitor) produced modest Week-24 SVR35 (~10%) alongside prolonged median OS (~29.9 months) in Phase 2 MYF2001, FDA agreed to Overall Survival as the primary endpoint in Phase 3 IMpactMF (NCT04576156). However, multi-year OS trials in heterogeneous R/R MF face subsequent-therapy crossover, myelosuppression dropouts, and binary late futility risk—underscoring the urgent FDA RDEA opportunity for validated composite surrogates combining VAF clearance, digital marrow fibrosis regression (>=1 grade), and transfusion independence.", "primary_citations": ["NCT04576156", "ORPHA:824"]}
{"id": "mf-bench-021", "category": "clinical_trial_forensics", "difficulty": "medium", "question": "Many post-ruxolitinib salvage clinical trials struggle with slow accrual because community patients and oncologists refuse a mandatory 14-to-28 day JAK inhibitor washout period ('washout terror' due to acute spleen pain and systemic cytokine rebound). How did the Phase 3 POIESIS trial of navtemadlin (NCT06479135) architecturally solve this operational and biological bottleneck?", "choices": {"A": "By requiring surgical splenectomy in all participants 30 days prior to screening", "B": "By enrolling TP53 bi-allelic mutant blast-phase AML patients exclusively, in whom MDM2 inhibition is synthetically lethal", "C": "By substituting high-dose intravenous cyclophosphamide during a 6-week ruxolitinib washout", "D": "By enrolling JAKi-naive patients onto ruxolitinib lead-in and randomizing suboptimal ruxolitinib responders at Week 18-24 to add-on navtemadlin (oral MDM2 inhibitor restoring wild-type TP53 apoptosis in CD34+ MF clones) vs placebo on top of stable continuous ruxolitinib—eliminating washout cytokine rebound while isolating true add-on clonal efficacy and excluding TP53-mutant non-responders"}, "correct_choice": "D", "required_reasoning_keywords": ["POIESIS", "navtemadlin", "NCT06479135", "MDM2", "TP53"], "rationale": "POIESIS (NCT06479135) addresses three classic MF trial pitfalls simultaneously: (1) zero ruxolitinib washout via run-in identification of suboptimal responders followed by randomized add-on dosing; (2) avoiding frontline ceiling dilution in patients who already respond completely to ruxolitinib alone; and (3) mandatory TP53 wild-type selection, because MDM2 inhibitors require intact functional p53 to induce apoptosis in JAK2/CALR-mutant CD34+ progenitors (and would otherwise positively select pre-existing TP53-mutant subclones; GEO:GSE226340).", "primary_citations": ["NCT06479135", "GEO:GSE226340"]}
{"id": "mf-bench-022", "category": "clinical_trial_forensics", "difficulty": "hard", "question": "Evaluate the mechanistic complementarity and clinical positioning of nuvisertib (TP-3654, NCT04181788) and selinexor (SENTRY, NCT04562389 / NCT05210790) in Myelofibrosis relative to BCL-XL inhibition (navitoclax):", "choices": {"A": "Nuvisertib is an anti-CD19 CAR-T therapy requiring fludarabine lymphodepletion", "B": "Both nuvisertib and selinexor act exclusively by degrading mature circulating platelets via BCL-XL proteolysis", "C": "Nuvisertib selectively inhibits PIM1 kinase—a direct STAT5 transcriptional target upregulated during Type I JAK2 persistence that phosphorylates BAD and stabilizes MYC/cytokine translation—achieving spleen, symptom, and bone-marrow cytokine/fibrosis signals WITHOUT on-target platelet apoptosis (sparing mature platelets that depend on BCL-XL), while selinexor inhibits XPO1 nuclear export to retain tumor-suppressor cargoes (p53, IkB, FOXO) in the nucleus alongside JAK inhibition", "D": "Selinexor is a selective JH2 V617F allosteric binder with zero nuclear-transport activity"}, "correct_choice": "C", "required_reasoning_keywords": ["nuvisertib", "PIM1", "NCT04181788", "selinexor", "XPO1"], "rationale": "Mature human platelets require BCL-XL (BCL2L1) as an intrinsic survival clock, giving navitoclax unavoidable dose-limiting thrombocytopenia. By contrast, PIM1 kinase (targeted by nuvisertib, NCT04181788) is transcriptionally driven by STAT5 in MPN clones—and Pim1 knockout completely abrogates JAK2 V617F myelofibrosis in vivo without causing severe thrombocytopenia in humans (enrolling platelets >=25 x 10^9/L). Meanwhile, selinexor (XPO1 inhibitor, SENTRY NCT04562389 / NCT05210790) blocks exportin-1 nuclear export of p53, p21, and NF-kB/IkB regulators to deepen clonal and spleen responses in combination with ruxolitinib.", "primary_citations": ["NCT04181788", "NCT04562389", "NCT05210790", "NCT04472598"]}
{"id": "mf-bench-023", "category": "clinical_trial_forensics", "difficulty": "hard", "question": "Why does manual pathologist WHO marrow fibrosis grading (MF-0, MF-1, MF-2, MF-3) frequently underpower secondary antifibrotic endpoints in 24-to-48 week Phase 2/3 Myelofibrosis trials, and what quantitative pathology upgrade directly increases statistical power?", "choices": {"A": "Bone marrow reticulin fibers dissolve completely in standard formalin fixation, making WSI scanning impossible", "B": "Ordinal 4-tier manual WHO grading exhibits 30-40% inter-observer hematopathologist discordance, focal biopsy sampling heterogeneity, and coarse step-function insensitivity (e.g., a 45% reduction in continuous reticulin fiber density and collagen I/III bundling within Grade MF-2 registers as '0 grade change'); continuous whole-slide image (WSI) morphometry of reticulin density, collagen cross-linking, osteosclerosis, and megakaryocyte spatial clustering topology resolves sub-grade remodeling", "C": "Manual WHO grading has 99.9% kappa concordance across community hospitals, so antifibrotic endpoints never fail due to measurement noise", "D": "Peripheral blood MCV alone is FDA-qualified as a complete replacement for bone marrow histology in PMF"}, "correct_choice": "B", "required_reasoning_keywords": ["inter-observer", "MF-0", "WSI", "reticulin", "megakaryocyte"], "rationale": "Ordinal WHO grading compresses continuous extracellular matrix remodeling into four coarse bins with 30-40% inter-reader variability and ignores quantitative spatial organization of atypical megakaryocyte clusters vs resolving stroma. Foundation-model WSI pathomics (continuous reticulin/trichrome fiber density, branch-point density, and megakaryocyte-stromal proximity graphs) paired with peripheral VAF kinetics provides continuous longitudinal effect sizes suited for FDA Rare Disease Endpoint Advancement (RDEA) qualification (GEO:GSE144568, GEO:GSE156644).", "primary_citations": ["GEO:GSE144568", "GEO:GSE156644", "PMID:24767860", "NCT04603495"]}
{"id": "mf-bench-024", "category": "clinical_trial_forensics", "difficulty": "medium", "question": "A 71-year-old patient with JAK2 V617F+ Primary Myelofibrosis presents with massive symptomatic splenomegaly, baseline platelet count 36 x 10^9/L, hemoglobin 8.4 g/dL, and normal thiamine levels. Based on pivotal Phase 3 trial eligibility and FDA labeling across PERSIST-2 (NCT02055781), JAKARTA (NCT01437787), COMFORT-I (NCT00952289), and MOMENTUM (NCT04173494), which approved therapy is specifically indicated and mechanistically adapted for baseline platelets <50 x 10^9/L?", "choices": {"A": "Pacritinib 200 mg BID (PERSIST-2, NCT02055781), a JAK1-sparing JAK2/IRAK1/ACVR1 inhibitor granted FDA Accelerated Approval specifically for MF with severe thrombocytopenia (platelets <50 x 10^9/L) where full-dose ruxolitinib and fedratinib are restricted", "B": "Full-dose ruxolitinib 25 mg BID (COMFORT-I enrolled exclusively platelets <25 x 10^9/L)", "C": "Navitoclax monotherapy, which selectively elevates platelet counts via BCL-XL agonism", "D": "Fedratinib 800 mg QD without thiamine monitoring, which carries zero hematologic or neurologic warnings"}, "correct_choice": "A", "required_reasoning_keywords": ["pacritinib", "PERSIST-2", "NCT02055781", "IRAK1", "platelets <50"], "rationale": "COMFORT-I/II required baseline platelets >=100 x 10^9/L and JAKARTA (fedratinib, NCT01437787—which also carries a Boxed Warning for Wernicke encephalopathy requiring thiamine monitoring) enrolled platelets >=50 x 10^9/L. PERSIST-2 (NCT02055781) prospectively evaluated thrombocytopenic MF (<100 x 10^9/L and specifically <50 x 10^9/L), supporting pacritinib's FDA approval at full 200 mg BID dosing in patients with platelets <50 x 10^9/L via JAK1-sparing JAK2 + NF-kB/IRAK1 + ACVR1 inhibition.", "primary_citations": ["NCT02055781", "NCT01437787", "NCT00952289", "NCT04173494"]}
{"id": "mf-bench-025", "category": "orphan_venture_economics", "difficulty": "medium", "question": "A seed-stage biotech developing a mutant-selective JAK2 V617F JH2 degrader for adult Myelofibrosis (US prevalence ~15,000-25,000 patients, well below the 200,000 statutory threshold; ORPHA:824) secures FDA Orphan Drug Designation (ODD) in FY2026. Which exact combination of statutory economic incentives does ODD confer—and does adult Primary Myelofibrosis qualify for a transferable Rare Pediatric Disease Priority Review Voucher (PRV)?", "choices": {"A": "100% waiver of the FY2026 FDA PDUFA NDA/BLA clinical application fee (~$4.68M cash savings), 25% federal Orphan Drug Tax Credit (ODTC) on qualified clinical testing expenses, 7 years of US orphan market exclusivity upon approval, and eligibility for FDA OOPD clinical grants—WITHOUT Rare Pediatric PRV eligibility, because MF is predominantly an adult-onset neoplasm (median age 65-70) whereas transferable PRVs require a Rare Pediatric Disease such as Dyskeratosis Congenita (ORPHA:1775)", "B": "50% federal tax credit, 20 years of automatic patent extension, and a guaranteed $150M Rare Pediatric PRV upon adult PMF approval", "C": "Exemption from Phase 1/2 safety testing and automatic Medicare Part D formulary monopoly across all non-orphan solid tumors", "D": "Zero PDUFA fee waiver unless US prevalence is fewer than 500 total patients"}, "correct_choice": "A", "required_reasoning_keywords": ["PDUFA", "25%", "7 years", "200,000", "Rare Pediatric"], "rationale": "Under the Orphan Drug Act (prevalence <200,000 US patients) and FY2026 user-fee schedules, ODD provides: (1) 100% waiver of the ~$4,682,003 PDUFA clinical NDA/BLA filing fee, (2) 25% ODTC tax credit on qualified US clinical trial expenses (adjusted from 50% by the 2017 TCJA), (3) 7 years of indication-specific US market exclusivity (10 years in EU), and (4) FDA OOPD grant eligibility. Crucially, venture models must NOT conflate adult ODD with Rare Pediatric Disease PRVs ($100M-$158M secondary market value), which require serious/life-threatening manifestations primarily affecting individuals aged 0-18 (e.g., pediatric Dyskeratosis Congenita / Telomere Biology Disorders, ORPHA:1775).", "primary_citations": ["ORPHA:824", "ORPHA:1775"]}
{"id": "mf-bench-026", "category": "orphan_venture_economics", "difficulty": "medium", "question": "A technical founder with computational biology expertise and $100K in initial angel/founder capital wants to validate an in-silico-designed JAK2 V617F JH2 degrader or single-cell stromal antifibrotic (GEO:GSE144568, GEO:GSE156644) to reach institutional Seed/Series A readiness with minimal equity dilution. Which sequenced non-dilutive + venture-philanthropy capital stack is best calibrated to actual award mechanisms?", "choices": {"A": "Wait to raise a $60M Series A before running a single biochemical selectivity assay, since federal SBIR grants require owning a 20,000 sq ft wet lab", "B": "Apply only for CMS Medicare Part B device reimbursement codes prior to compound synthesis", "C": "Rely exclusively on crowdsourced GoFundMe donations collected by automated bots posting inside r/mpn and HealthUnlocked", "D": "Stack an MPN Research Foundation MPN Challenge translational grant (~$250K, 0% dilution) + NIH/NCI or NHLBI SBIR Phase I ($300K-$400K, 0% dilution) using fee-for-service CRO biochemical/BaF3/CD34+ assays to generate selective VAF/fibrosis proof-of-concept, then unlock NCI SBIR Phase II ($2.0M) + Blood Cancer United (formerly LLS) Therapy Acceleration Program (TAP, $1M-$5M strategic venture philanthropy) or ARPA-H milestone awards for IND-enabling & Phase 1b execution"}, "correct_choice": "D", "required_reasoning_keywords": ["MPN Research Foundation", "SBIR", "Therapy Acceleration Program", "ARPA-H", "non-dilutive"], "rationale": "Virtual/CRO-executed hit-to-lead validation ($120K-$350K for 30-50 custom analogs + DiscoverX JH2/JH1 TR-FRET + primary MF CD34+ co-cultures) pairs ideally with MPN Research Foundation (~$250K) and NCI/NHLBI SBIR Phase I ($300K-$400K, 0% equity dilution). Once mutant-selective VAF or stromal fibrosis reversal is demonstrated, startups can stack SBIR Phase II/IIB ($2M-$4.5M), FDA OOPD trial grants ($1M-$3M), ARPA-H cooperative agreements, and Blood Cancer United (LLS) TAP ($1M-$5M+ strategic co-investment) to cross the preclinical-to-Phase 1b valley of death with 3x-8x founder equity efficiency.", "primary_citations": ["GEO:GSE144568", "GEO:GSE156644", "ORPHA:824"]}
{"id": "mf-bench-027", "category": "orphan_venture_economics", "difficulty": "hard", "question": "Evaluate the regulatory and commercial wedge for a zero-wet-lab AI/EHR clinical decision support startup deploying an AIMF vs Triple-Negative PMF + Dual Iron-Hepcidin triage tool across community rheumatology and hematology networks. How can such a company generate compliant B2B revenue within 6-12 months BEFORE completing a multi-year FDA De Novo / 510(k) SaMD submission?", "choices": {"A": "Market an opaque black-box autonomous treatment-prescribing bot directly to patients on social media without physician oversight or HIPAA Business Associate Agreements", "B": "Bill Medicare $50,000 per algorithmic query under emergency surgical transplant DRG codes", "C": "Launch a clinician-facing non-device Clinical Decision Support (CDS) workflow under 21st Century Cures Act Sec. 3060(a) (displaying transparent, independently reviewable Mayo/French AIMF criteria, MIPSS70+ v2.0 inputs, and TSAT/ferritin/hepcidin logic so the hematologist independently reviews the basis), monetizing immediately via reference-lab reflex NGS/pathology partnerships, value-based payer avoidance of futile ~$200K/yr JAKi/HSCT misrouting, and IRB-consented biopharma trial-enrichment / External Control Arm contracts", "D": "Scrape private Smart Patients and Facebook caregiver messages without consent to sell identifiable patient leads to pharmaceutical sales reps"}, "correct_choice": "C", "required_reasoning_keywords": ["21st Century Cures", "Clinical Decision Support", "External Control Arm", "HIPAA", "AIMF"], "rationale": "Under Section 3060(a) of the 21st Century Cures Act and FDA CDS guidance, software that analyzes structured EHR labs/pathology criteria (ANA, DAT, MCV, TSAT, ferritin, ASXL1/SRSF2 clonality, megakaryocyte clustering) and presents transparent, guideline-cited logic enabling the clinician to independently review the basis for the recommendation qualifies as non-device CDS—while WSI morphometry can deploy initially as RUO centralized trial biomarker SaaS ($300K-$1.5M/trial) or CLIA lab-developed morphometry prior to FDA 510(k)/De Novo SaMD expansion. Unconsented forum scraping and black-box autonomous prescribing violate ethical and FDA rules.", "primary_citations": ["PMID:38342652", "NCT07362225", "ORPHA:824"]}
{"id": "mf-bench-028", "category": "orphan_venture_economics", "difficulty": "hard", "question": "An AI drug-repurposing startup identifies a safe, off-patent oral small molecule that collapses the S100A8/A9 -> TLR4 -> GLI1+ stromal myofibroblast loop in human MF single-cell perturbation models (GEO:GSE156644) andEvery Cure /CDC-style knowledge graphs. Why do pure generic molecules without formulation, dosing, or combination IP struggle to attract traditional Series A venture capital—and what dual regulatory/financing structure resolves this 'generic repurposing paradox'?", "choices": {"A": "Off-patent molecules are legally barred from receiving FDA Orphan Drug Designation under any circumstance", "B": "Without composition-of-matter barriers, generic substitution at the pharmacy erodes commercial pricing even if efficacy is proven; founders resolve this either commercially via an FDA 505(b)(2) NDA with novel orphan-specific dosing/modified-release formulation or fixed-dose JAKi combination IP backed by 7-year Orphan Drug exclusivity, OR via non-dilutive foundation/federal trials (CDCN/Every Cure, MPNRF, FDA OOPD, ARPA-H) and payer shared-savings outcomes contracts", "C": "505(b)(2) NDAs require repeating 100% of preclinical animal toxicology from scratch at >$50M cost", "D": "Repurposed antifibrotics can only be commercialized as unregulated dietary supplements"}, "correct_choice": "B", "required_reasoning_keywords": ["505(b)(2)", "7-year", "Orphan Drug exclusivity", "Every Cure", "CDCN"], "rationale": "Generic substitution occurs when an identical dosage strength/form is already marketed, creating market failure for unpatented repurposing (highlighted by CDCN & Every Cure in iMCD sirolimus NCT03933904). Where commercial VC backing is sought, pairing FDA 505(b)(2) reliance on existing human safety packages (cutting pre-IND cost 60-75%) with a differentiated strength/release profile or fixed-dose combination patent + 7-year FDA Orphan Drug exclusivity blocks generic cross-labeling; where pure off-patent generics are optimal for patients, Every Cure, CDCN, MPNRF, and ARPA-H fund pivotal trials non-dilutively.", "primary_citations": ["GEO:GSE156644", "NCT03933904", "ORPHA:93685", "ORPHA:824"]}
{"id": "mf-bench-029", "category": "orphan_venture_economics", "difficulty": "medium", "question": "Between 2022 and 2024, three single-asset late-stage Myelofibrosis biotech acquisitions clustered tightly between $1.7B and $2.9B (CTI BioPharma/pacritinib -> Sobi $1.7B; Sierra Oncology/momelotinib -> GSK $1.9B; MorphoSys/pelabresib -> Novartis $2.9B), alongside ruxolitinib exceeding $4.5B/yr global revenue. What structural market dynamic drives multi-billion-dollar M&A valuations in an indication with only ~15,000-25,000 US Myelofibrosis patients?", "choices": {"A": "Concentrated hematology prescriber footprint (enabling lean 50-80 rep specialty commercial launches), chronic orphan specialty pricing (~$180K-$260K+/patient/yr with strong Medicare Part D/commercial coverage for life-threatening blood cancers), N=120-350 registrational trial sizes, late-2020s incumbent patent cliffs, and pipeline expansion into >150,000 JAK2+ Polycythemia Vera and Essential Thrombocythemia patients", "B": "Myelofibrosis drugs require N=15,000 cardiovascular outcomes trials costing $1.5B each", "C": "Complete absence of FDA clinical efficacy requirements for hematologic malignancies", "D": "Mandatory over-the-counter pharmacy stockpiling by municipal public health departments"}, "correct_choice": "A", "required_reasoning_keywords": ["orphan", "Polycythemia Vera", "commercial", "patent cliff", "specialty"], "rationale": "Orphan hematology exhibits exceptional capital efficiency: registrational trials enroll 120-350 patients, US prescribers are concentrated in academic MPN centers and hematology-oncology groups, chronic oral therapies command specialty oncology reimbursement, and a truly mutant-selective, non-myelosuppressive JAK2 V617F or CALR agent can expand upstream from ~20,000 US MF patients into >300,000 US PV and ET patients to intercept clonal progression decades earlier (ORPHA:824, NCT06313593, NCT06034002).", "primary_citations": ["ORPHA:824", "NCT04173494", "NCT02055781", "NCT04603495"]}
{"id": "mf-bench-030", "category": "orphan_venture_economics", "difficulty": "medium", "question": "An autonomous AI venture-discovery agent is tasked with gathering patient-reported unmet needs on 'ruxolitinib washout anxiety', transfusion fatigue, and diagnostic delays across MPN Voice (HealthUnlocked), r/mpn, Smart Patients, MPN PROGRESSion Registry (NCT07362225), and the Lupus Research Alliance. Which engagement protocol satisfies the Rare Disease Venture Atlas's mandatory ethical governance rules?", "choices": {"A": "Deploy headless browser bots to register fake caregiver accounts, scrape registration-gated Smart Patients threads, and auto-DM patients with clinical trial referral links", "B": "Offer uncompensated 4-hour mandatory interview marathons in exchange for unvalidated algorithmic dosing advice", "C": "Train a commercial diagnostic LLM directly on scraped Reddit usernames and clinical lab screenshots without moderator contact or de-identification", "D": "Engage formally through foundation scientific leadership and registry governance (e.g., MPNRF PROGRESSion Registry NCT07362225, HealthTree Cure Hub, Blood Cancer United CTSC, Lupus Therapeutics), prohibit automated forum posting or unconsented narrative scraping, compensate patient/caregiver advisors at fair market value ($100-$250/hr) in fatigue-aware 30-45 minute co-design sessions, and secure central IRB review + explicit HIPAA authorization before ingesting patient-level EHR/FHIR data"}, "correct_choice": "D", "required_reasoning_keywords": ["NCT07362225", "IRB", "HIPAA", "fair market value", "scraping"], "rationale": "Rare disease patient communities are high-trust, vulnerable ecosystems harmed by bot spam and extractive data scraping. Compliant translational validation routes all research through institutional registries (MPN PROGRESSion NCT07362225, HealthTree, CDCN ACCELERATE, LuCIN), enforces zero bot posting and zero unconsented scraping of identifiable or gated posts, compensates lived-experience advisors ($100-$250/hr in low-burden 30-45 min sessions), returns plain-language findings, and maintains strict IRB + HIPAA authorization boundaries.", "primary_citations": ["NCT07362225", "ORPHA:824"]}
